E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Short Bowel Syndrome (SBS) |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with SBS with intestinal failure have a reduced absorption function in the intestines. Shortened intestines also lead to a changed hormone production. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10049416 |
E.1.2 | Term | Short-bowel syndrome |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety and tolerability of FE 203799 in patients with SBS with intestinal.
|
|
E.2.2 | Secondary objectives of the trial |
To assess the pharmacodynamics (PD) of FE 203799 in patients with SBS with intestinal failure
To assess the trough concentration and the post dose plasma concentration of FE 203799 in patients with SBS with intestinal failure
To evaluate markers indicative of a pharmacological effect
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Males and females with SBS secondary to surgical resection of the small intestine
2.18-80 years of age
3.Body Mass Index (BMI) between 16.0 and 32.0 (both inclusive)
4.Patients with a jejuno- or ileostomy and a faecal wet weight excretion of at least 1500 g/day, as recorded within the last 18 months according to the patient’s medical record
5.Parenteral support ≥3 times/week for ≥12 months according to the patient’s medical record
6.At least 6 months since last surgical bowel resection
7.Willing to adhere to a defined oral intake of fluids on certain days as required by the protocol (and based on the individual’s routine daily consumption)
8.Women of childbearing potential must agree to use an adequate method of contraception during the trial and for 60 days after the end-of-trial visit. Adequate methods of contraception include intrauterine device or hormonal contraception (oral contraceptive pill, depot injections or implant, transdermal depot patch or vaginal ring). To be considered sterilised or infertile, females must have undergone surgical sterilisation (bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be post-menopausal (defined as at least 12 months amenorrhoea may be confirmed with follicle-stimulating hormone [FSH] test) if there is doubt)
9. Male subjects must commit to use barrier contraception (e.g. condom) during the trial and for 2 weeks after the end-of-trial visit. |
|
E.4 | Principal exclusion criteria |
1.Pregnancy or lactation
2.Positive results on the human immunodeficiency virus (HIV), hepatitis B and/or C tests
3.A history of clinically significant intestinal adhesions and/or chronic abdominal pain
4.Require chronic systemic narcotics for treatment of pain that exceeds an amount corresponding to 80 mg of morphine per day
5.History of cancer or clinically significant lymphoproliferative disease within ≤5 years, except for adequately treated basal cell skin cancer
6.History of gallstone within the past 3 years. Gallstones with subsequent cholecystectomy to resolve the issues is acceptable
7.Inflammatory bowel disease (IBD) patients who have not been on a stable drug treatment regimen for at least the past 4 weeks
8.Evidence of active IBD in the past 12 weeks
9.Visible blood in the stool within the last 3 months
10.Catheter sepsis experienced within the last 3 months
11.Decompensated heart failure (New York Heart Association [NYHA] class III-IV, see Appendix 12.2) and/or known coronary heart disease defined as unstable angina pectoris and/or myocardial infarction within the last 6 months prior to screening
12.Radiation enteritis, scleroderma or other condition of intestinal dysmotility, coeliac disease, refractory or tropical sprue
13.History of alcohol and/or drug abuse within the last 12 months
14.Inadequate hepatic function as defined by: bilirubin >upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) >2.0 × ULN; alkaline phosphatase (ALP) >2.5 × ULN; or international normalised ratio (INR) >1.5 × ULN
15.Inadequate renal function as defined by serum creatinine or blood urea nitrogen >2.5 × ULN
16.Unplanned hospitalisation of >24 hours duration within 1 month before the screening visit
17. Changes in systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, infliximab or other biologic therapy/immune modifiers within 3 months of screening
18.Any use of growth hormone, glutamine or growth factors such as native GLP 2 or GLP 2 analogue within the last 3 months
19.Any use of antibiotics within the last 30 days
20.Participation in another clinical trial within the last 3 months and during this trial
21.Previously been randomised in this trial
22.Loss of blood or donation of blood or plasma >500 mL within 3 months prior to screening
23.Patient not capable of understanding or not willing to adhere to the trial visit schedules and other protocol requirements
24.For any other reason judged not eligible by the investigator
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Adverse events (AEs; type, frequency and intensity), vital signs (systolic and diastolic blood pressure, heart rate), electrocardiogram (ECG; intervals, rhythm and morphology), clinical chemistry, haematology, haemostasis and urinalysis
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline run-in to End of trail visit, in total during 42 weeks |
|
E.5.2 | Secondary end point(s) |
•Change from baseline in urinary output over 48 hours at the end of the treatment period (Days 26-28)
•Change from baseline in urinary output over 48 hours immediately after first dose in the treatment period (Days 1-3)
•Change from baseline in urinary Na+ levels over 48 hours immediately after first dose (Days 1-3)
•Change from baseline in urinary Na+ levels over 48 hours at the end of the treatment period (Days 26-28)
•Change from baseline in PS volume during the treatment period (Days 21+22)
•Change from baseline in oral fluid intake during the treatment period (Days 21+22)
•Change from baseline in plasma citrulline levels on Day 8 and at the end of the treatment period (Day 29)
•Change from baseline in lean body mass and other body composition parameters (bone mineral content and fat mass) using dual-energy X-ray absorptiometry (DEXA) scan at the end of the treatment period (Day 29)
•Plasma concentration of FE 203799 at 72 hours (C72h) and trough concentration of FE 203799 (Ctrough)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
From baseline run-in to End of trail visit, in total during 42 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Local tolerability and changes in urine output, parenteral support and oral fluid intake |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
The above describes Part A. Part B will be a single arm open label design |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A patient is considered to have completed the trial if he or she has received all 4 IMP injections in treatment period 1 and at least 3 IMP injections in each treatment period 2 and 3, and if he or she has completed final safety assessments at the end-of-trial visit.
The trial will be closed when all patients have completed Visit 29 (end-of-trial visit).
LVFS 31Dec2019 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |